drugset / Trial / NCT03400254
Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
Phase 1/2
Withdrawn
Abramson Cancer Center at Penn Medicine
Breast Cancer Research Foundation · collabHoosier Cancer Research Network · collabPfizer · collabTranslational Breast Cancer Research Consortium · collab
RandomizedSingle-groupSingle-blindTreatment
Summary
This clinical trial will assess the safety and early efficacy of the role of gedatolisib and hydroxychloroquine in early-stage breast cancer patients with residual disease and evidence of disseminated tumor cells (DTCs) on bone marrow aspirate after neoadjuvant chemotherapy (NACT) and definitive surgery.
Timeline
- Start
- 2019-02-26
- Primary completion
- 2019-08-30
- Completion
- 2019-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gedatolisib | Small molecule | 150 mg | Intravenous |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |